Ensoma cuts staff again to focus on lead gene therapy for rare immune disease

Boston‑based biotech Ensoma announced another round of layoffs as it narrows its efforts to its sole clinical candidate, EN‑374, aimed at treating X‑linked chronic granulomatous disease (X‑CGD).

EN‑374 is a gene‑therapy approach that delivers a functional copy of the CYBB gene to patients' stem cells using a virus‑like vector, with the goal of restoring normal immune function. The therapy is currently in a phase 1/2 trial.

The company did not disclose how many employees were affected by the latest cuts, but earlier in November it laid off 37 staff members as part of a restructuring.

A company spokesperson said the restructuring is intended to align resources behind EN‑374 and to validate the platform for future therapeutic areas.